Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.98M Sell
25,516
-5,627
-18% -$2.01M 0.73% 38
2025
Q4
$10.2M Sell
31,143
-301
-1% -$95.5K 0.69% 38
2025
Q3
$8.87M Sell
31,444
-2,602
-8% -$755K 0.58% 45
2025
Q2
$9.51M Sell
34,046
-477
-1% -$135K 0.63% 40
2025
Q1
$10.8M Sell
34,523
-1,511
-4% -$446K 0.76% 34
2024
Q4
$9.39M Sell
36,034
-11,869
-25% -$3.52M 0.6% 41
2024
Q3
$15.2M Sell
47,903
-3,111
-6% -$1.02M 0.86% 31
2024
Q2
$15.9M Sell
51,014
-123,606
-71% -$36.3M 0.9% 29
2024
Q1
$49.6M Buy
174,620
+18,733
+12% +$5.48M 2.78% 7
2023
Q4
$44.9M Sell
155,887
-10,968
-7% -$2.99M 2.5% 8
2023
Q3
$44.8M Sell
166,855
-43,567
-21% -$10.9M 2.61% 8
2023
Q2
$46.7M Sell
210,422
-1,515
-0.7% -$352K 2.57% 7
2023
Q1
$51.2M Buy
211,937
+9,173
+5% +$2.25M 2.99% 5
2022
Q4
$53.3M Sell
202,764
-517
-0.3% -$139K 2.95% 6
2022
Q3
$45.8M Buy
203,281
+732
+0.4% +$177K 2.89% 5
2022
Q2
$49.3M Buy
202,549
+3,431
+2% +$841K 3.01% 5
2022
Q1
$48.2M Buy
199,118
+1,617
+0.8% +$372K 2.53% 6
2021
Q4
$44.4M Buy
197,501
+4,345
+2% +$917K 2.26% 7
2021
Q3
$41.1M Buy
193,156
+21,128
+12% +$4.86M 2.27% 7
2021
Q2
$41.9M Buy
172,028
+11,171
+7% +$2.75M 2.35% 6
2021
Q1
$40M Sell
160,857
-4,708
-3% -$1.12M 2.3% 6
2020
Q4
$38.1M Sell
165,565
-4,100
-2% -$945K 2.28% 6
2020
Q3
$43.1M Sell
169,665
-2,750
-2% -$681K 2.78% 4
2020
Q2
$40.7M Buy
172,415
+125,988
+271% +$28.7M 2.85% 5
2020
Q1
$9.41M Sell
46,427
-3,830
-8% -$837K 0.77% 27
2019
Q4
$12.1M Buy
50,257
+641
+1% +$141K 0.81% 26
2019
Q3
$9.6M Sell
49,616
-1,960
-4% -$376K 0.68% 39
2019
Q2
$9.5M Buy
51,576
+671
+1% +$120K 0.69% 37
2019
Q1
$9.67M Sell
50,905
-1,280
-2% -$244K 0.73% 36
2018
Q4
$10.2M Sell
52,185
-433
-0.8% -$84.5K 0.84% 25
2018
Q3
$10.9M Sell
52,618
-8,007
-13% -$1.58M 0.79% 27
2018
Q2
$11.2M Sell
60,625
-35,281
-37% -$6.24M 0.86% 23
2018
Q1
$16.4M Sell
95,906
-820
-0.8% -$151K 1.24% 10
2017
Q4
$16.8M Sell
96,726
-1,026
-1% -$182K 1.24% 11
2017
Q3
$18.2M Buy
97,752
+8,215
+9% +$1.46M 1.4% 9
2017
Q2
$15.4M Buy
89,537
+8,348
+10% +$1.36M 1.2% 12
2017
Q1
$13.3M Buy
81,189
+12,960
+19% +$2.15M 1.09% 15
2016
Q4
$9.98M Sell
68,229
-1,376
-2% -$207K 0.85% 27
2016
Q3
$11.6M Sell
69,605
-1,795
-3% -$304K 0.99% 17
2016
Q2
$10.9M Buy
71,400
+10,680
+18% +$1.66M 0.88% 21
2016
Q1
$9.1M Buy
60,720
+6,450
+12% +$958K 0.78% 30
2015
Q4
$8.81M Buy
54,270
+13,129
+32% +$2.06M 0.77% 37
2015
Q3
$5.69M Buy
41,141
+771
+2% +$122K 0.52% 50
2015
Q2
$6.2M Buy
40,370
+1,250
+3% +$200K 0.51% 47
2015
Q1
$6.25M Buy
39,120
+4,200
+12% +$661K 0.49% 46
2014
Q4
$5.56M Buy
34,920
+8,810
+34% +$1.37M 0.59% 31
2014
Q3
$3.67M Buy
+26,110
New +$3.41M 0.42% 39
2014
Q2
Sell
-17,010
Closed -$2.1M 84
2014
Q1
$2.1M Buy
17,010
+5,690
+50% +$690K 0.24% 55
2013
Q4
$1.29M Buy
11,320
+770
+7% +$87.6K 0.15% 64
2013
Q3
$1.18M Sell
10,550
-3,850
-27% -$417K 0.16% 67
2013
Q2
$1.42M Buy
+14,400
New +$1.49M 0.19% 64

Other funds holding AMGN

Cullinan Associates's AMGN Position: Q1 2026 in Review

Cullinan Associates reduced its Amgen (AMGN) stake by 18% in Q1 2026, selling an estimated $2.01M and leaving 25,516 shares worth $8.98M. The position accounts for 0.73% of the portfolio, ranked #38.

Cullinan Associates first reported a position in AMGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $53.3M in Q4 2022. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Cullinan Associates held 25,516 shares of Amgen worth $8.98M as of Q1 2026.
  • Cullinan Associates sold 5,627 Amgen shares in Q1 2026, an estimated $2.01M.
  • Amgen made up 0.73% of Cullinan Associates's portfolio in Q1 2026, its #38 holding.
  • Cullinan Associates first reported a position in Amgen in Q2 2013 and has held it in 51 quarters since.
  • Cullinan Associates's Amgen position peaked at $53.3M in Q4 2022.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.